Head-To-Head Comparison: Iovance Biotherapeutics (NASDAQ:IOVA) and eXoZymes (NASDAQ:EXOZ)

eXoZymes (NASDAQ:EXOZ) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Profitability

This table compares eXoZymes and Iovance Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Volatility & Risk

eXoZymes has a beta of 3.14, indicating that its share price is 214% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for eXoZymes and Iovance Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1	0	0	0	1.00
Iovance Biotherapeutics	2	2	7	0	2.45

Iovance Biotherapeutics has a consensus price target of $8.89, indicating a potential upside of 3.36%. Given Iovance Biotherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than eXoZymes.

Earnings & Valuation

This table compares eXoZymes and Iovance Biotherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70,000.00	874.97	-$9.16 million	($1.19)	-5.55
Iovance Biotherapeutics	$263.50 million	14.78	-$390.98 million	($0.73)	-11.78

eXoZymes has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Iovance Biotherapeutics beats eXoZymes on 8 of the 14 factors compared between the two stocks.

About eXoZymes

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.